CClinicalTrials.gg
CompletedNCT07275957Updated Oct 5, 2026

Combined Nutrition and Exercise Interventions in Women With Breast Cancer History

An interventional study of Mediterranean Diet Counseling and Supervised Strength Training Program in Breast Cancer Survivors, sponsored by University of Alicante. Completed at 1 site in Spain. Open to female participants aged 30 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by University of Alicante · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 2 months after the study started (first participant enrolled Sep 2023, registered Nov 2025).
Updated Oct 5, 2026Now CompletedGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
30 Years to 65 Years
Sex
Female
01

Study summary

This study aims to evaluate the effects of a combined dietary-nutritional and physical exercise intervention on physical, physiological, and psychological outcomes in women who are breast cancer survivors. Participants will be randomly assigned to different intervention groups involving dietary modification, exercise training, or their combination, compared to a control group. The program will last 12 weeks and will include pre- and post-intervention assessments of body composition, metabolic parameters, functional capacity, and quality of life.

The primary goal is to assess improvements in physical fitness, body composition, and emotional well-being, as well as to identify potential synergistic effects of combined interventions in this population.

Read the detailed description

Breast cancer survivors often experience long-term physical and psychological side effects derived from treatment, such as fatigue, loss of muscle mass, metabolic alterations, and reduced quality of life. Lifestyle interventions involving nutrition and exercise have demonstrated significant potential to mitigate these effects and promote overall recovery.

This randomized controlled clinical trial will include adult female breast cancer survivors who have completed their primary oncological treatment. Participants will be divided into six parallel groups:

  1. Control group - no intervention.
  2. Mediterranean diet group (MD) - individualized nutritional plan based on Mediterranean dietary patterns.
  3. Strength training group (ST) - supervised resistance exercise sessions.
  4. Endurance training group (ET) - supervised aerobic exercise sessions.
  5. Combined training group (CT) - combination of strength and endurance training.
  6. Combined diet and exercise group (MD+CT) - simultaneous application of Mediterranean diet and combined training.

The intervention will last 12 weeks, during which participants in the intervention groups will attend supervised sessions and receive continuous nutritional guidance. Assessments will be performed at baseline and after 12 weeks, including anthropometric and body composition analysis, metabolic and inflammatory markers, physical fitness testing, dietary intake, and psychological well-being scales.

This study seeks to identify the most effective strategy-dietary, physical, or combined-for improving health outcomes, functionality, and emotional recovery in breast cancer survivors, contributing to the development of comprehensive post-treatment rehabilitation programs.

02

Conditions studied

  • Breast Cancer Survivors

Keywords

  • Breast cancer survivors
  • Exercise intervention
  • Nutritional intervention
  • Mediterranean diet
  • Physical rehabilitation
  • Quality of life
  • Body composition
  • Strength training
  • Aerobic exercise
  • Combined training
  • Lifestyle modification
03

In context

Lead sponsor

University of Alicante is the lead sponsor of 27 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Women aged 30 to 65 years.
  • Previous diagnosis of breast cancer (stages I-III) confirmed by medical records.
  • Completion of primary oncological treatment (surgery, radiotherapy, chemotherapy, and/or hormone therapy) at least 3 months before enrollment.
  • Absence of active cancer or evidence of recurrence.
  • Medical clearance to perform physical exercise.
  • Willingness to participate in dietary and/or exercise interventions for 12 weeks.
  • Ability to attend evaluation and intervention sessions and comply with study procedures.
  • Signed written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Active cancer, metastasis, or ongoing chemotherapy or radiotherapy.
  • Severe cardiovascular, respiratory, renal, hepatic, or metabolic disease that contraindicates exercise.
  • Musculoskeletal or neurological conditions limiting participation in physical activity.
  • Severe psychiatric disorders or cognitive impairment affecting adherence to the intervention.
  • Current participation in another clinical trial or structured lifestyle intervention.
  • Use of dietary supplements, appetite regulators, or pharmacological agents affecting metabolism during the study period.
  • Pregnancy, breastfeeding, or intention to become pregnant during the study.
  • Inability to comply with the intervention schedule or follow-up assessments.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • No intervention
    Arm 1 - Control Group

    Participants will not receive any specific dietary or exercise intervention. They will be asked to maintain their usual lifestyle and dietary habits during the 12-week study period. General health recommendations based on national guidelines will be provided at baseline.

  • Experimental
    Arm 2 - Mediterranean Diet Group (MD)

    Participants will receive individualized nutritional counseling promoting adherence to a Mediterranean dietary pattern, emphasizing fruits, vegetables, legumes, whole grains, olive oil, nuts, fish, and moderate dairy intake. Processed and high-sugar foods will be limited. Dietitians will provide personalized follow-up and adjustments every two weeks to ensure adherence.

    Behavioral: Mediterranean Diet Counseling

  • Experimental
    Arm 3 - Strength Training Group (ST)

    Participants will perform a 12-week supervised resistance training program focused on improving muscular strength and functional capacity. Sessions will be conducted three times per week, lasting approximately 60 minutes, and include major muscle groups using elastic bands, free weights, and bodyweight exercises. Training load will progressively increase according to individual capacity.

    Behavioral: Supervised Strength Training Program

  • Experimental
    Arm 4 - Endurance Training Group (ET)

    Participants will follow a structured aerobic exercise program consisting of walking, cycling, or treadmill sessions three times per week for 12 weeks. The intensity will be moderate (60-75% of estimated maximal heart rate), gradually progressing as tolerated. The goal is to enhance cardiorespiratory fitness and overall endurance.

    Behavioral: Supervised Endurance Training Program

  • Experimental
    Arm 5 - Combined Training Group (CT)

    Participants will perform both strength and aerobic training during the 12-week intervention. Each session (3 per week, 60-70 minutes) will include resistance exercises targeting major muscle groups followed by aerobic activity at moderate intensity. The program aims to improve both muscular and cardiovascular performance synergistically.

    Behavioral: Combined Strength and Endurance Training Program

  • Experimental
    Arm 6 - Mediterranean Diet plus Combined Training Group (MD+CT)

    Participants will simultaneously receive the Mediterranean Diet counseling and participate in the Combined Training program for 12 weeks. The objective is to assess the synergistic effects of diet and exercise on physical, physiological, and psychological health in breast cancer survivors.

    Behavioral: Combined Mediterranean Diet and Exercise Program

Interventions

  • BehavioralMediterranean Diet Counseling

    Individualized nutritional counseling based on Mediterranean diet principles, emphasizing the intake of fruits, vegetables, legumes, whole grains, nuts, olive oil, and fish, while reducing red meat, processed foods, and added sugars. Sessions will be held biweekly to ensure adherence and promote long-term dietary behavior change.

  • BehavioralSupervised Strength Training Program

    A structured resistance exercise program performed three times per week for 12 weeks. Each 60-minute session will include exercises for major muscle groups using elastic bands, dumbbells, or body weight, progressively increasing intensity to improve muscle strength and endurance.

  • BehavioralSupervised Endurance Training Program

    A structured aerobic exercise program consisting of walking, cycling, or treadmill training three times per week for 12 weeks. Exercise intensity will range from 60% to 75% of the estimated maximal heart rate, progressively adjusted to enhance cardiovascular fitness and fatigue resistance.

  • BehavioralCombined Strength and Endurance Training Program

    A combined exercise protocol including both resistance and aerobic components within each 60-70-minute session, three times per week for 12 weeks. Strength exercises will precede moderate-intensity aerobic work to improve overall physical performance and functional capacity.

  • BehavioralCombined Mediterranean Diet and Exercise Program

    Comprehensive lifestyle intervention combining Mediterranean diet counseling with the supervised combined training program. Participants will receive individualized diet plans and attend three supervised exercise sessions per week. The intervention targets improvements in body composition, physical fitness, and emotional well-being.

06

What researchers measure

Primary outcomes

  1. Change in Fat-Free Mass (kg)

    To evaluate changes in fat-free mass after the 12-week intervention, measured by bioimpedance analysis (BIODY XPERT ZM).

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Change in Fat Mass (%)

    To assess changes in total body fat percentage using bioimpedance analysis.

    Time frame: Baseline and Week 12

  2. Change in Body Weight (kg)

    To determine body weight variation during the 12-week intervention.

    Time frame: Baseline and Week 12

  3. Change in Body Mass Index (kg/m²)

    To evaluate changes in BMI calculated as weight divided by height squared.

    Time frame: Baseline and Week 12

  4. Change in Waist Circumference (cm)

    To assess central adiposity changes by measuring waist circumference.

    Time frame: Baseline and Week 12

  5. Change in Handgrip Strength (kg)

    To evaluate upper-body muscular strength using a digital hand dynamometer.

    Time frame: Baseline and Week 12

  6. Change in Lower-Limb Strength (kg)

    To assess lower-limb strength through isometric tests using a load cell or force platform.

    Time frame: Baseline and Week 12

  7. Change in Functional Capacity (6-Minute Walk Test Distance, m)

    To evaluate cardiorespiratory endurance using the 6-minute walk test.

    Time frame: Baseline and Week 12

  8. Change in Balance Performance

    To assess dynamic balance and postural control

    Time frame: Baseline and Week 12

  9. Change in Flexibility (Sit-and-Reach Test, cm)

    To evaluate flexibility of the posterior chain through the sit-and-reach test.

    Time frame: Baseline and Week 12

  10. Change in Maximal Oxygen Uptake (VO₂max, mL/kg/min)

    To determine changes in aerobic capacity using an incremental treadmill test with indirect calorimetry (METALYZ-ERR 3 B-R3 spirometer).

    Time frame: Baseline and Week 12

  11. Change in Total Cholesterol (mg/dL)

    To evaluate lipid profile variations by measuring total cholesterol concentration.

    Time frame: Baseline and Week 12

  12. Change in HDL Cholesterol (mg/dL)

    To assess cardioprotective lipid changes.

    Time frame: Baseline and Week 12

  13. Change in LDL Cholesterol (mg/dL)

    To measure changes in LDL cholesterol levels.

    Time frame: Baseline and Week 12

  14. Change in Triglycerides (mg/dL)

    To determine variations in triglyceride concentration.

    Time frame: Baseline and Week 12

  15. Change in Fasting Glucose (mg/dL)

    To assess metabolic health by measuring fasting plasma glucose.

    Time frame: Baseline and Week 12

  16. Change in C-Reactive Protein (mg/L)

    To evaluate systemic inflammation using CRP levels.

    Time frame: Baseline and Week 12

  17. Change in Interleukin-6 (pg/mL)

    To measure inflammatory status via IL-6 concentration.

    Time frame: Baseline and Week 12

  18. Change in Fatigue (FACIT-F Questionnaire Score)

    Description: Fatigue will be assessed using the Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-F). This questionnaire consists of 13 items rated on a 5-point Likert scale ranging from 0 ("not at all") to 4 ("very much"), reflecting fatigue experienced during the past 7 days. The total score is calculated by summing the item scores (after reverse scoring where applicable). Range: 0-52. Interpretation: Higher scores indicate less fatigue and therefore a better functional status, while lower scores reflect greater fatigue severity.

    Time frame: Baseline and Week 12

  19. Change in Sleep Quality (PSQI Total Score)

    Description: Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI), a 19-item self-reported questionnaire that evaluates sleep quality and disturbances over the previous month. The items are grouped into seven components (subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction), each scored from 0 to 3. The global PSQI score is the sum of the components (range 0-21). Range: 0-21. Interpretation: Higher scores indicate poorer sleep quality.

    Time frame: Baseline and Week 12

  20. Change in Physical Activity Level (IPAQ Total Score)

    Description: Physical activity levels will be evaluated using the International Physical Activity Questionnaire - Short Form (IPAQ-SF), which records the frequency and duration of walking, moderate, and vigorous activities over the past 7 days. The results are expressed as total metabolic equivalent minutes per week (MET-min/week) and can be categorized into three levels: low, moderate, or high activity. Range: 0 to unlimited MET-min/week. Interpretation: Higher scores indicate higher physical activity levels.

    Time frame: Baseline and Week 12

  21. Change in Dietary Adherence (Mediterranean Diet Adherence Screener Score)

    Description: Adherence to the Mediterranean diet will be assessed using the PREDIMED Questionnaire, a validated 14-item questionnaire evaluating key dietary habits such as olive oil use, fruit and vegetable consumption, fish intake, and limitation of red meat and sweets. Each affirmative answer scores 1 point, yielding a total score from 0 (minimal adherence) to 14 (maximal adherence). Range: 0-14. Interpretation: Higher scores indicate better adherence to the Mediterranean dietary pattern.

    Time frame: Baseline and Week 12

07

Study locations

1 site
  • European Institute Of Exercise and Health
    Elche, Alicante 03203, Spain
08

Updates

1 registry update since Sep 25, 2026
Status
Active, not recruiting→Completed
changed Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Active, not recruiting→Completed
    + 1 other change: date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07275957
Lead sponsor
University of Alicante
Responsible party
Prof. Dr. Alejandro Martínez-Rodríguez (Full Professor of Health Sciences, University of Alicante) — Principal investigator
First posted
Dec 10, 2025
Start date
Sep 1, 2023
Primary completion
Dec 31, 2025
Completion
Jun 30, 2026
Last update
Oct 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion